Li Pei, Zhang Ruijie, Gan Yibo, Wang Liyuan, Zhao Chen, Luo Lei, Zhang Chengmin, Zhou Qiang
Department of Orthopedic Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Department of Respiratory Medicine, the Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Biomed Pharmacother. 2017 Apr;88:260-266. doi: 10.1016/j.biopha.2016.12.137. Epub 2017 Jan 19.
Osteogenic protein (OP)-1 delivery into discs has achieved some success in disc regeneration in animals, though conflicting outcomes exist. This study aimed to systematically review the animal studies that assessed the effect of OP-1 on disc regeneration. Relevant literature was searched in the following databases: PubMed, MEDLINE, EMBASE, the Cochrane Library, China National Knowledge Internet (CNKI) and Chinese BioMedical Literature Database (CBM). Animal species, disc degeneration model, OP-1 delivery method, and follow-up methodology including disc histology, disc matrix alteration, disc height, MRI T2 signal intensity and OP-1 treatment complications were extracted and reviewed. Among 15 eligible studies, direct OP-1 protein injection into the disc was reported in 10 studies whereas cell-based or viral-based OP-1 gene transfer into the disc was reported in 5 studies. Although one study using a spontaneous canine disc degeneration model reported negative findings, all other studies (10 in rabbit, 1 in canine and 3 in rat) indicated that OP-1 delivery was effective in retarding disc degeneration and regenerating discs. The adverse effect of OP-1 delivery (i.e., extradiscal new bone formation) was reported in one study. In conclusion, OP-1 delivery offers a feasible option to biologically treat degenerated discs in animals, especially in rodent rabbit and rat models. However, more animal studies are needed to test the safety of the current OP-1 delivery means. Additionally, care should be taken when OP-1 delivery is used to treat human disc degeneration due to the differences between human and animal discs.
成骨蛋白（OP）-1注入椎间盘在动物椎间盘再生方面已取得一定成功，尽管结果存在矛盾。本研究旨在系统回顾评估OP-1对椎间盘再生影响的动物研究。在以下数据库中检索相关文献：PubMed、MEDLINE、EMBASE、Cochrane图书馆、中国知网（CNKI）和中国生物医学文献数据库（CBM）。提取并回顾动物种类、椎间盘退变模型、OP-1注入方法以及随访方法，包括椎间盘组织学、椎间盘基质改变、椎间盘高度、MRI T2信号强度和OP-1治疗并发症。在15项符合条件的研究中，10项研究报告了将OP-1蛋白直接注入椎间盘，而5项研究报告了基于细胞或病毒的OP-1基因导入椎间盘。尽管一项使用自发性犬椎间盘退变模型的研究报告了阴性结果，但所有其他研究（10项在兔，1项在犬，3项在大鼠）均表明，注入OP-1可有效延缓椎间盘退变并使椎间盘再生。一项研究报告了注入OP-1的不良反应（即椎间盘外新骨形成）。总之，注入OP-1为生物学治疗动物退变椎间盘提供了一种可行选择，尤其是在啮齿类兔和大鼠模型中。然而，需要更多动物研究来测试当前OP-1注入方法的安全性。此外，由于人和动物椎间盘存在差异，在使用OP-1注入治疗人类椎间盘退变时应谨慎。
